IN8bio, Inc.
INABHealthcare|Biotechnology|US
$0.93
+0.10 (+11.63%)
DCF Value
$5.49
Tangible Book / Share
$0.73
Cash / Share
$0.72
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05664243 A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | Glioblastoma | P1P2 | Active | 4 | Open-label | Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells |
| NCT03533816 Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | Acute Myeloid Leukemia, Chronic Myeloid Leukemia | P1 | Recruiting | 38 | Open-label | EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion) |